Page 178 - 2019_10 resto del Mondo_web

V.G. Ramakrishnan et al.
ogenous leukemia and solid tumors. Genes
Dev. 2012;26(4):305-311.
39. Rooswinkel RW, van de Kooij B, de Vries E,
et al. Antiapoptotic potency of Bcl-2 pro- teins primarily relies on their stability, not binding selectivity. Blood. 2014;123(18): 2806-2815.
40. Torres-Adorno AM, Lee J, Kogawa T, et al. Histone deacetylase inhibitor enhances the efficacy of MEK inhibitor through NOXA- mediated MCL1 degradation in triple-nega- tive and inflammatory breast cancer. Clin Cancer Res. 2017;23(16):4780-4792.
41. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311-322.
42. Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in
patients with relapsed or refractory non- Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826-833.
43. Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401-2409.
44. Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58(9):1-17.
45. Caenepeel, S, Brown, SP, Belmontes B, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established thera- pies. Cancer Discov. 2018;8(12):1582-1597.
46. Surolia I, Bates SE. Entinostat finds a path: a new study elucidates effects of the histone deacetylase inhibitor on the immune sys- tem. Cancer. 2018;124(24):4597-4600.
47. Stubbs MC, Kim W, Bariteau M, et al. Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL. Clin Cancer Res. 2015;21(10):2348-2358.
48. Mithraprabhu S, Khong T, Jones SS, Spencer A. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. Br J Haematol. 2013;162(4):559-562.
49. Mithraprabhu S, Kalff A, Chow A, Khong T, Spencer A. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014;9(11):1511-1520.
50. Kalin JH, Wu M, Gomez AV, et al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018;9(1):53.
2074
haematologica | 2019; 104(10)